Profile data is unavailable for this security.
About the company
Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH). Its product candidate Seralutinib, also known as GB002, is an investigational inhaled, small molecule, platelet-derived growth factor receptor (PDGFR), colony-stimulating factor 1 receptor (CSF1R), and c-KIT inhibitor, being evaluated in a Phase III clinical trial for the treatment of PAH. In contrast to the three classes of marketed vasodilatory therapies for PAH, its seralutinib has the potential to reverse pathological remodeling by addressing mechanisms that underlie PAH. Inhaled seralutinib, which is designed to act on both isoforms of the PDGFR, α and β, as well as the CSF1R and c-KIT pathways. In addition to PAH, seralutinib holds the potential as a therapeutic option for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD).
- Revenue in USD (TTM)0.00
- Net income in USD-179.82m
- Incorporated2015
- Employees135.00
- LocationGossamer Bio Inc3013 Science Park RdSAN DIEGO 92121-1101United StatesUSA
- Phone+1 (858) 922-0718
- Fax+1 (302) 636-5454
- Websitehttps://www.gossamerbio.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioatla Inc | 0.00 | -123.46m | 156.35m | 65.00 | -- | 2.21 | -- | -- | -2.58 | -2.58 | 0.00 | 1.47 | 0.00 | -- | -- | 0.00 | -71.49 | -48.72 | -84.01 | -57.35 | -- | -- | -- | -6,651.71 | -- | -- | 0.00 | -- | -- | -- | -15.95 | -- | -37.01 | -- |
Cardiff Oncology Inc | 610.00k | -40.25m | 157.38m | 31.00 | -- | 2.58 | -- | 258.00 | -0.901 | -0.901 | 0.0137 | 1.36 | 0.0068 | -- | 1.14 | 19,677.42 | -44.55 | -31.24 | -50.10 | -33.56 | -- | -- | -6,594.92 | -7,819.23 | -- | -- | 0.00 | -- | 26.42 | 5.22 | -7.07 | -- | 157.91 | -- |
Tevogen Bio Holdings Inc | 0.00 | -62.57m | 159.68m | -- | -- | -- | -- | -- | -0.4043 | -0.4043 | 0.00 | -0.5867 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -8.74 | 42.99 | -- | -- | -- | -41.32 | -- | -- | -- |
Achieve Life Sciences Inc | 0.00 | -29.82m | 162.18m | 22.00 | -- | -- | -- | -- | -1.53 | -1.53 | 0.00 | -0.0684 | 0.00 | -- | -- | 0.00 | -120.85 | -86.31 | -860.46 | -119.59 | -- | -- | -- | -- | -- | -10.66 | 1.10 | -- | -- | -- | 29.60 | -- | -14.51 | -- |
ProQR Therapeutics NV | 10.25m | -30.25m | 163.52m | 157.00 | -- | 3.80 | -- | 15.96 | -0.3735 | -0.3735 | 0.1265 | 0.5285 | 0.0616 | -- | 0.332 | 65,267.54 | -17.94 | -35.51 | -21.82 | -40.51 | -- | -- | -291.18 | -926.31 | -- | -- | 0.3229 | -- | 118.51 | 10.58 | 56.35 | -- | 34.45 | -- |
Gossamer Bio Inc | 0.00 | -179.82m | 167.40m | 135.00 | -- | 2.66 | -- | -- | -1.38 | -1.38 | 0.00 | 0.2785 | 0.00 | -- | -- | 0.00 | -61.54 | -57.43 | -74.38 | -64.38 | -- | -- | -- | -- | -- | -15.09 | 0.769 | -- | -- | -- | 21.61 | -- | -- | -- |
Scpharmaceuticals Inc | 13.59m | -54.81m | 168.01m | 135.00 | -- | 4.50 | -- | 12.36 | -1.42 | -1.42 | 0.353 | 1.03 | 0.1243 | 0.7569 | -- | 100,688.90 | -50.13 | -38.23 | -55.33 | -42.31 | 71.96 | -- | -403.22 | -1,360.16 | 6.40 | -18.35 | 0.5105 | -- | -- | -- | -48.79 | -- | -- | -- |
bluebird bio Inc | 21.73m | -91.17m | 171.28m | 323.00 | -- | 0.4327 | -- | 7.88 | -0.7446 | -0.7446 | 0.2139 | 2.08 | 0.0383 | -- | -- | 67,263.16 | -16.08 | -33.02 | -21.50 | -37.14 | -10.08 | 19.44 | -419.62 | -4,044.31 | 1.42 | -- | 0.00 | -- | -1.77 | -36.71 | 52.62 | -- | -26.66 | -- |
Capricor Therapeutics Inc | 25.18m | -22.29m | 172.32m | 101.00 | -- | 7.54 | -- | 6.84 | -0.8708 | -0.8708 | 0.9403 | 0.7256 | 0.4627 | -- | 4.61 | 249,287.80 | -40.96 | -54.12 | -82.59 | -75.13 | -- | -- | -88.52 | -316.25 | -- | -- | 0.13 | -- | 886.81 | 72.02 | 23.20 | -- | 45.27 | -- |
Alpha Tau Medical Ltd | 0.00 | -29.16m | 173.48m | 121.00 | -- | 2.05 | -- | -- | -0.4203 | -0.4203 | 0.00 | 1.21 | 0.00 | -- | -- | 0.00 | -25.63 | -- | -26.99 | -- | -- | -- | -- | -- | -- | -- | 0.0623 | -- | -- | -- | 13.64 | -- | -- | -- |
Regulus Therapeutics Inc | 0.00 | -30.04m | 173.48m | 30.00 | -- | 2.53 | -- | -- | -1.59 | -1.59 | 0.00 | 1.05 | 0.00 | -- | -- | 0.00 | -77.55 | -53.74 | -104.84 | -76.96 | -- | -- | -- | -715.58 | -- | -- | 0.0592 | -- | -- | -- | -6.05 | -- | 94.54 | -- |
Seres Therapeutics Inc | 126.33m | -113.72m | 175.17m | 233.00 | -- | -- | -- | 1.39 | -0.897 | -0.897 | 0.9829 | -0.3322 | 0.3572 | -- | -- | 542,167.40 | -32.15 | -41.51 | -43.48 | -54.13 | -- | -- | -90.02 | -170.14 | 1.48 | -18.38 | 1.79 | -- | 1,672.24 | 34.91 | 54.54 | -- | 32.72 | -- |
Mediwound Ltd | 18.69m | -6.72m | 177.02m | 100.00 | -- | 5.44 | -- | 9.47 | -0.768 | -0.768 | 2.07 | 3.43 | 0.3209 | 6.28 | 2.87 | 186,860.00 | -11.53 | -24.48 | -14.35 | -32.92 | 19.15 | 43.27 | -35.94 | -38.43 | 4.33 | -- | 0.1674 | -- | -29.48 | 40.60 | 65.73 | -- | 64.66 | -- |
ASP Isotopes Inc | 433.03k | -16.29m | 181.99m | 76.00 | -- | 11.17 | -- | 420.28 | -0.5016 | -0.5016 | 0.0131 | 0.3331 | 0.0216 | -- | -- | 5,697.76 | -81.39 | -- | -109.02 | -- | 32.09 | -- | -3,762.82 | -- | -- | -251.76 | 0.0378 | -- | -- | -- | -229.34 | -- | -- | -- |
Telomir Pharmaceuticals Inc | 0.00 | -13.07m | 183.58m | 1.00 | -- | 51.59 | -- | -- | -0.48 | -0.48 | 0.00 | 0.1202 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -2.40 | 0.0285 | -- | -- | -- | -1,430.39 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
Fidelity Management & Research Co. LLCas of 31 Dec 2023 | 12.26m | 5.44% |
Invus Public Equities Advisors LLCas of 31 Dec 2023 | 12.06m | 5.35% |
The Vanguard Group, Inc.as of 31 Dec 2023 | 11.57m | 5.13% |
EcoR1 Capital, LLCas of 31 Dec 2023 | 9.20m | 4.08% |
Octagon Capital Advisors LPas of 31 Dec 2023 | 9.19m | 4.07% |
Platinum Investment Management Ltd.as of 31 Dec 2023 | 6.95m | 3.08% |
Eversept Partners LPas of 31 Dec 2023 | 6.43m | 2.85% |
Farallon Capital Management LLCas of 31 Dec 2023 | 6.13m | 2.72% |
SilverArc Capital Management LLCas of 31 Dec 2023 | 6.13m | 2.72% |
Citadel Advisors LLCas of 31 Dec 2023 | 6.10m | 2.71% |